Clinical Pharmacology of Antimicrobials in Children
|
|
- Alberta Hancock
- 5 years ago
- Views:
Transcription
1 Clinical Pharmacology of Antimicrobials in Children Joe Standing MRC Methodology Fellow & Antimicrobial Pharmacist UCL Institute of Child Health Great Ormond Street Hospital for Children March / 43
2 2 / 43
3 What you should get (AKA Learning Objectives): Know the pharmacology of some common antimicrobials Understand what pharmacokinetics means, and how it links with clinical effect (pharmacodynamics) Recognise how pharmacokinetics scales in children 3 / 43
4 Overview Antimicrobial pharmacology Introduction to pharmacokinetics Linking pharmacokinetics to clinical effect Scaling pharmacokinetics in children Case studies 4 / 43
5 Antimicrobial pharmacology: β - lactams Irreversible binding to DD-transpeptidase Inhibits cross-linking of cell wall peptidoglycan Requires near saturation for lysis Many organisms produce β - lactamase e.g. Penicillins, cephalosporinns, carbapenems (>50% of antimicrobials used are β - lactams) 5 / 43
6 Antimicrobial pharmacology: Other cell-wall inhibitors Glycopeptides: e.g. vancomycin, teicoplanin Inhibits peptidoglycan chain elongation Mainly Gram positive activity Antifungal agents: Azoles inhibit ergosterol synthesis Echinocandins inhibit glucan synthesis Polyene agents, e.g. amphotericin, bind to ergosterol creating transmembrane pore 6 / 43
7 Antimicrobial pharmacology: Nucleic acid synthesis inhibitors Inhibition of precursors: e.g. sulphonamides, trimethoprim Inhibition of folate synthesis Inhibition of replication: e.g. quinolones Inhibits ligase part of topoisomerase II meaning DNA is not re-joined Direct DNA damage: e.g. metronidazole Following non-enzymatic reduction in anaerobic environment, various metabolites and cause DNA cross-linkage/direct damage Transcription: e.g. rifamycins Inhibition of prokaryotic RNA polymerase 7 / 43
8 Antimicrobial pharmacology: Protein synthesis inhibitors mrna translation: e.g. aminoglycosides, tetracyclines Bind to 30S ribosome subunit Inaccurately formed proteins, incorporate to cell wall, can lead to further antimicrobial penetration Protein formation: e.g. macrolides, chloramphenicol Bind to 50S ribosome subunit Peptidyl transferase inhibition 8 / 43
9 Antimicrobial pharmacology: antiretrovirals Reverse transcriptase inhibitors: Nucleoside or non-nucleoside Inhibit viral incorporation to host DNA Protease inhibitors: Cause production of defective virus Entry inhibitors: Block viral entry e.g. via CCR5 Integrase inhibitors: Inhibit viral incorporation to host DNA 9 / 43
10 Overview Antimicrobial pharmacology Introduction to pharmacokinetics Linking pharmacokinetics to clinical effect Scaling pharmacokinetics in children Case studies 10 / 43
11 Introduction to Pharmacokinetics: Absorption Bioavailability F [0, 1] F = Fa Fg Fh 11 / 43
12 Introduction to Pharmacokinetics: Distribution Important factors: flow, partition, protein/tissue binding 12 / 43
13 Introduction to Pharmacokinetics: Metabolism Major sites: LIVER, gi tract Minor sites: kidneys, lungs Enzymatic reactions: make things more water soluble Phase I: Cytochrome P450 (e.g. CYP3A4, CYP2D6) Phase II: Multiple (e.g. UGT) Well-stirred liver model: CL H = FQ CL int FQ + CL int. (1) 13 / 43
14 Introduction to Pharmacokinetics: Elimination 14 / 43
15 Introduction to Pharmacokinetics: Some data Descriptive analysis: AUC, Cmax, tmax, elimination half-life How about a model? 15 / 43
16 Introduction to Pharmacokinetics: One-compartment model C(t) = Dose k a V (k a k) (e k t e ka t ), k = CL V. Note: models such as this describe/predict circulating concentrations. Physiologically-bases systems pharmacology models can help predict tissue concentrations. (2) 16 / 43
17 Overview Antimicrobial pharmacology Introduction to pharmacokinetics Linking pharmacokinetics to clinical effect Scaling pharmacokinetics in children Case studies 17 / 43
18 Linking Pharmacokinetics and Pharmacodynamics 18 / 43
19 Pharmacological Response Law of mass action: Drug (D) combining with Receptor (R) [D] + [R] [DR]. (3) Quantities of interest: k 1, rate of association k 2, rate of dissociation K D, dissociation constant K D = k 2 k 1 = [D] [R]. (4) [DR] 19 / 43
20 Concentration-Effect: Hill curve Effect = E max C γ EC50 γ + C γ. (5) 20 / 43
21 Pharmacokinetic compared with pharmacodynamic time-course 21 / 43
22 Antimicrobial PKPD: Simplest case McKinnon 2004: 22 / 43
23 Antimicrobial PKPD: Static in vitro experiments Elucidating PKPD in vitro e.g. Drusano 2004: 23 / 43
24 Linking PK and PD Quite often: PD time course PK time course. Hysteresis: 24 / 43
25 Antimicrobial PKPD: Dynamic in vitro experiments e.g. Nielsen 2011 Antibacterial dosing usually based on worst-case scenario (no immune component) Scaling to children involves accounting for pharmacokinetic ontogeny 25 / 43
26 Antimicrobial PKPD: e.g. HIV disease progression After starting antiretroviral treatment, CD4 lymphocytes recover, and circulating virus is suppressed: 26 / 43
27 Basic model of HIV 27 / 43
28 Overview Antimicrobial pharmacology Introduction to pharmacokinetics Linking pharmacokinetics to clinical effect Scaling pharmacokinetics in children Case studies 28 / 43
29 Children are not small adults Pharmacokinetic differences: Absorption: Gastric ph, motility, bile salts, flora, milk feeds Distribution: body water, body fat, plasma proteins Metabolism: liver size, metabolising enzymes Elimination: liver size, metabolising enzymes 29 / 43
30 Children are small adults; neonates and infants are immature children Maturation is continuous By 2 years of age, most processes involved with drug handling are mature Differences in children above 2 years and adults mainly due to size How to scale for size? Volume tends to be linear Clearance and metabolic processes follow allometric relationship: Y = a W b. (6) where: Y = biological characteristic; W = weight; a and b are derived coefficients. 30 / 43
31 Kleiber 1947: Drug Clearance: Allometric Scaling 31 / 43
32 Drug Clearance: Allometric Scaling Burger 2007: 32 / 43
33 Drug Clearance: Allometric Scaling Anderson 2007: 33 / 43
34 Overview Antimicrobial pharmacology Introduction to pharmacokinetics Linking pharmacokinetics to clinical effect Scaling pharmacokinetics in children Case studies 34 / 43
35 Antimicrobial PKPD: Dynamic in vitro experiments Gentamicin: narrow therapeutic index aminoglycoside Dosing in neonates poorly defined Nielsen et al: Collected and modelled PK data in neonates Performed static and dynamic in vitro experiments versus E. coli and fitted model including adaptive resistance Combined the in vivo PK modelling with the in vitro PD modelling to investigate different dosing regimens 35 / 43
36 Antimicrobial PKPD: Dynamic in vitro experiments 36 / 43
37 Case study 2: HIV Personalised medicine HIV patients often experience medication side-effects Minimising dosing whilst still ensuring viral suppression is attractive Prague 2012, activated cells model: 37 / 43
38 Prague / 43
39 Case study 3: drug-induced neutropenia Lots of drugs deplete neutrophils (side effect) Quantifying, predicting and avoiding neutropenia is important: In 2009, 3 people died of neutropenic sepsis for every 1000 cancer diagnoses. (Prevention and management of neutropenic sepsis in cancer patients: NICE 2012) 39 / 43
40 Case study 3: Neutropenia time course Some analysts have focussed on time to nadir or depth of nadir; is this ideal? 40 / 43
41 Case study 3: Friberg model In 2002 Friberg described neutrophil maturation with a system of ODEs dp dt = k prol P (1 E drug ) (C(0)/C(t)) γ k tr P dt 1 = k tr P k tr T 1 dt dt 2 = k tr T 1 k tr T 2 dt dt 3 = k tr T 2 k tr T 3 dt dc dt = k tr T 3 k tr C. (7) 41 / 43
42 Case study 3: Friberg 2002 Unlike empirical models linking depth of/time to nadir with dose, the mechanistic approach predicts the full time-course Because underlying system is captured, the model can be used for extrapolations (e.g. Soto 2011) and dose adjustments (e.g. Wallin 2009) 42 / 43
43 What you should get (AKA Learning Objectives): Know the pharmacology of some common antimicrobials Understand what pharmacokinetics means, and how it links with clinical effect (pharmacodynamics) Recognise how pharmacokinetics scales in children 43 / 43
Chapter 10. Antimicrobials. PowerPoint Lecture Slides for MICROBIOLOGY ROBERT W. BAUMAN
PowerPoint Lecture Slides for MICROBIOLOGY ROBERT W. BAUMAN Chapter 10 Antimicrobials Antimicrobial Drugs Chemotherapy - The use of drugs to treat a disease Antimicrobial drugs - Interfere with the growth
More informationAntimicrobial Drugs. Antimicrobial Drugs. The dawn of antibiotics. Alexander Fleming. Chain and Florey. Antibiotics
Antimicrobial Drugs Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease Antimicrobial drugs: Interfere with the growth of microbes within a host Antibiotic: Substance produced by a microbe
More informationAntimicrobial and Antibacterial Agents
Antimicrobial and Antibacterial Agents Contents Introduction Classification of antimicrobial drugs Special terms Mechanism of action Resistance of antimicrobial agent Introduction Joseph Lister 1867 -
More informationChapter 10 Controlling Microbial Growth in the Body: Antimicrobial Drugs. 10/15/ MDufilho
Chapter 10 Controlling Microbial Growth in the Body: Antimicrobial Drugs 10/15/2017 1 MDufilho The History of Antimicrobial Agents Drugs Chemicals that affect physiology in any manner Chemotherapeutic
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationEMA Workshop Non-Clinical Models to Identify PK/PD Indices and PD Targets In Vitro
EMA Workshop Non-Clinical Models to Identify PK/PD Indices and PD Targets In Vitro G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida In Vitro There are
More informationMICROORGANISM AND CHEMOTHERAPEIC MATERIALS
MICROORGANISM AND CHEMOTHERAPEIC MATERIALS Chemotherapeutic substances are antimicrobials derived from chemical substances. Antibiotics are antimicrobials obtained from bacteria or fungi CHEMOTHERAPYTIC
More informationThe general concept of pharmacodynamics
Asian PK/PD Educational Workshop The general concept of pharmacodynamics modeling the antibacterial effects relations PK / PD This part uses material from presentations of H. Derendorf (Gainesville, Fla.)
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 27 July 2000 CPMP/EWP/2655/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationReflection paper on the use of extrapolation in the development of medicines for paediatrics
1 2 3 9 October 2017 EMA/199678/2016 4 5 6 Reflection paper on the use of extrapolation in the development of medicines for paediatrics Draft Draft agreed by Biostatistics Working Party September 2017
More informationPHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models
PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models Student Objectives for this Chapter To understand the different types of concentration - effect relationships
More informationChapter 18. Viral Genetics. AP Biology
Chapter 18. Viral Genetics AP Biology What is a virus? Is it alive? DNA or RNA enclosed in a protein coat Viruses are not cells Extremely tiny electron microscope size smaller than ribosomes ~20 50 nm
More informationGenetika Mikroorganisme. dr. Agus Eka Darwinata, Ph.D
Genetika Mikroorganisme dr. Agus Eka Darwinata, Ph.D Gene and Genome The Central Dogma Mutation TOPIC Polimerase Chain Reaction Mechanism of Antimicrobioal Resistance Gene and Genome Genom adalah keseluruhan
More informationGuideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling
More informationPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra
More informationCurrent Guidelines for Drug-drug Interaction Evaluation
Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches
More informationHow antimicrobial agents work
Physical and Chemical Control of Microbes Physical Agents heat or radiation Chemical Agents disinfectants or antiseptics Important Terms 1. Sterilization process of killing all viable microbes 2. Bactericide
More informationModel of antibiotic action on bacterial growth
Model of antibiotic action on bacterial growth Martin R. Evans SUPA, School of Physics and Astronomy, University of Edinburgh, U.K. November 15, 2016 Collaborators: Philip Greulich (Edinburgh then Cambridge
More informationRole of PBPK based virtual trials modeling in generic product development and regulation
Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation
More informationRE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis
Suzanne Hill, M.D. Essential Medicines and Pharmaceutical Policies World Health Organization Geneva, Switzerland RE: CPMT-08-011 Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis
More information01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical.
Control of Microbial Growth Disinfectants and Antiseptics 1 Methods 2 Three approaches Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical elimination Cleaning Filtration
More informationAntifungal PK/PD Made Simple. David Andes, MD University of Wisconsin
Antifungal PK/PD Made Simple David Andes, MD University of Wisconsin PK/PD Concept Serum Drug Concentration Peak:MIC AUC:MIC Ratio Time Above MIC MIC Time Hypothesis and Concept There is an optimal drug
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationModel based approaches to target special populations with rational formulation and clinical design strategies
Model based approaches to target special populations with rational formulation and clinical design strategies David Good 3 rd FDA/PQRI Conference on Advancing Product Quality Modeling for Oral and Non-Oral
More informationPHICO THERAPEUTICS. SASPject: First in a new class of novel biological antibacterials. Dr Adam Wilkinson R&D Manager
PHICO THERAPEUTICS SASPject: First in a new class of novel biological antibacterials Dr Adam Wilkinson R&D Manager Phico Founded 2000 by CEO Dr Heather Fairhead 20 employees Raised 13 M from 140 shareholders
More informationPharmacokinetic & Pharmacodynamic Data Analysis
Pharmacokinetic & Pharmacodynamic Data Analysis CONCEPTS AND APPLICATIONS 4TH EDITION REVISED AND EXPANDED Table of Contents 1. 1.1 1.2 1.3 1.4 1.5 2. 2.1 2.2 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationINTRODUCTION TO CLINICAL PHARMACY
CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease
More informationWorkflow for PBPK Modeling to Support Pediatric Research and Development
Workflow for PBPK Modeling to Support Pediatric Research and Development Jeff Barrett, PhD Vice-President, Interdisciplinary Pharmacometrics Program Sanofi 1 Industrial Strength PBPK 2 Outline Industrial
More informationOral Delivery of Drugs
Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2014 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/2/2014 Pharmacokinetics (PK) and
More informationGuideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation
13 December 2018 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation Draft agreed
More informationGuideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating
1 2 3 26 July 2018 EMEA/CHMP/BMWP/31329/2005 Rev 1 Committee for Medicinal Product for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing recombinant granulocyte-colony
More informationKING KHALID UNIVERSITY
KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICAL CHEMISTRY COURSE SCHEDULE MALE SECTION BACHELOR OF PHARMACEUTICAL SCIENCES DEPARTMENT OF PHARMACEUTICAL CHEMISTRY MEDICINAL CHEMISTRY-3
More informationWhy Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development?
Why Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development? Weirong Wang, Ph.D. Biologics Clinical Pharmacology Why Knowledge of Translational PK/PD
More informationSetting Clinical Breakpoints/ECOFFS
23 rd August 2016 Setting Clinical Breakpoints/ECOFFS Robin A Howe Antimicrobial use in Primary Care An E. coli is grown from blood cultures Cefuroxime MIC 2mg/L Zone around CXM 30ug disc 27mm Is it sensitive?
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationPK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika
PK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika Heino Staß Institut für Klinische Pharmakologie Bayer HealthCare AG, Wuppertal, D Role of Clinical Pharmacology in the Development
More informationBeta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations
Beta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations Dr Shampa Das, Senior Lecturer, Molecular and Clinical Pharmacology,
More informationApplication of PBPK Models in Assessment of Bioequivalence
Application of PBPK Models in Assessment of Bioequivalence Robert Lionberger, Ph.D. Acting Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA
More informationBASIC PHARMACOKINETICS AND PHARMACODYNAMICS
BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics
More informationHow do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?
Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental
More informationBio 366: Biological Chemistry II Test #3, 100 points
Bio 366: Biological Chemistry II Test #3, 100 points READ THIS: Take a numbered test and sit in the seat with that number on it. Remove the numbered sticker from the desk, and stick it on the back of the
More informationChallenges in Antimicrobial Clinical Development. Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D
Challenges in Antimicrobial Clinical Development Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D New antibacterial agents approved in the United States 1983-2002 No.
More informationSequoia Education Systems, Inc. 1
Functional Diagnostic Medicine Training Program Mod 6 * FDMT 551A The Physiology and Biochemistry of (The Phases of Detoxification) Wayne L. Sodano, D.C., D.A.B.C.I. & Ron Grisanti, D.C., D.A.B.C.O., M.S.
More informationJan Willem van der Laan
First-in-human studies: Recent experiences in Europe Jan Willem van der Laan Section Pharmacological-Toxicological and Biotechnology Assessment Medicines Evaluation Board, Utrecht First-in-human trials
More informationBig Idea 3C Basic Review
Big Idea 3C Basic Review 1. A gene is a. A sequence of DNA that codes for a protein. b. A sequence of amino acids that codes for a protein. c. A sequence of codons that code for nucleic acids. d. The end
More informationLine extension of immediate release products
EMA/EGA Joint Workshop on the Impact of the Revised EMA Guideline on Modified Release Dosage Forms Line extension of immediate release products London, 30 th April 2014 Dr. Alfredo García Arieta Jefe de
More informationChimica Farmaceutica. Pharmacokinetics and related topics
Chimica Farmaceutica Pharmacokinetics and related topics INTRODUCTION In order to produce its intended effect, a drug must be present at an appropriate concentration in the fluid surrounding the effect
More informationPharmacogenomics information in SmPC
Pharmacogenomics information in SmPC SmPC training presentation Note: for full information refer to the European Commission's Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationMedicinal Chemistry II Introduction to antibiotics
Medicinal Chemistry II Introduction to antibiotics Dr. Mohammed Nooraldeen Al-Qattan History of microbials and anti-microbials Targets, spectrum, resistance, susceptibility, bacteriostatic vs bactericidal
More informationFirst UNGAP meeting Food-Drug Interactions Regulatory Aspects
First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal
More informationModule I: Introduction Lecture 1 4 February, 2010
Module I: Introduction 20.109 Lecture 1 4 February, 2010 Introduction to: Module Overview Fundamental concepts and techniques in molecular biology A powerful and accessible strategy (SELEX) for identifying
More informationGuideline for Bioequivalence Studies of Generic Products. December 22, 1997
Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products
More informationIsolation and screening of secondary metabolite producing microrganisms
Department of Biotechnology and Molecular Sciences Microbial Biotechnology Lab FLAVIA MARINELLI University of Insubria, Varese. Italy Isolation and screening of secondary metabolite producing microrganisms
More informationExperimental Design. Margaret A. Daugherty. Fall Michaelis Menton Kinetics and Inhibition. Lecture 14: Enzymes & Kinetics III E + S ES E + P
Lecture 14: Enzymes & Kinetics III Michaelis Menton Kinetics and Inhibition Margaret A. Daugherty Fall 2003 Experimental Design k 1 k cat E + S ES E + P k -1 I want to measure the reactivity of my enzyme
More informationDevelopment of paediatric formulations - points to consider
Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,
More informationUpdate on DDI Guidance of the FDA - In Vitro
Update on DDI Guidance of the FDA - In Vitro Xinning Yang, Ph.D. Policy lead Guidance & Policy Team (GPT) Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Complex picture of drug interactions in the body. This slide gives an idea of the complexity of drug disposition. Shown in this slide are many of the steps to getting
More informationUse of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited
Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs Nikunjkumar Patel, Simcyp Limited IVIVC and Its Components CONVOLUTION VALIDATION DECONVOLUTION MODELS IVIVC
More informationFig. 4. A two-compartment pharmacokinetic model.
3.4 Pharmacokinetic (PK) modeling and simulations Noora Sjöstedt, Wilma Kiander, Heidi Kidron 3.4.1 Introduction (Hanna Kortejärvi) Pharmacokinetic modeling and simulations can be performed with different
More informationConventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC
Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Nikunj Patel, Senior Research Scientist Simcyp (a Certara Company) AAPS
More informationModule I: Introduction
Module I: Introduction 20.109 Lecture 1 3 February, 2011 Introduction to: Module Overview Fundamental concepts and techniques in molecular biology Appreciating nucleic acids (RNA in particular) as more
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More information2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR
2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research Pharmacological Approaches to Address AR G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation
More informationNANYANG TECHNOLOGICAL UNIVERSITY SEMESTER I EXAMINATION CBC922 Medicinal Chemistry. NOVEMBER TIME ALLOWED: 120 min
AYAG TECLGICAL UIVERSITY SEMESTER I EXAMIATI 2006-2007 CBC922 Medicinal Chemistry VEMBER 2006 - TIME ALLWED 120 min ISTRUCTIS T CADIDATES 1. This examination paper contains TW (2) parts and comprises SIX
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT
More informationMODERN MEDICINAL CHEMISTRY
MODERN MEDICINAL CHEMISTRY JOHN B. TAYLOR, B.SC.,D.I.C.,PI..D., Senior Vice President, Central Research, Rhone-Poulenc Rorer, Dagenham Research Centre, Essex and PETER D. KENNEWELL, B.A.,M.A.,Ph.D., Scientific
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationApplied Biosystems/MDS Sciex LC/MS Users Meeting Daiichi Pure Chemicals Co., Ltd.
Introduction ADMET screening Drug-drug interaction Introduction ADMET screening 40% ADMET screening in vitro Absorption : Caco-2 Permeability, Transporter assay Distribution : Protein binding, Transporter
More informationIs Confirmatory PK/PD Modeling Possible?
Is Confirmatory PK/PD Modeling Possible? Chuanpu Hu, Ph.D. Director, Pharmacometrics Johnson & Johnson May 19, 2009 MBSW 2009 Outline PK/PD modeling why, how Exploratory vs. confirmatory: when to use which?
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationIntroduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
More informationPharmaceutical Drugs. Chemistry 199L. (Chapter 19)
Pharmaceutical Drugs Chemistry 199L Pharmaceutical Drugs (Chapter 19) Pain relievers and fever reducer: aspirin (Sunblock) (Aspirin) 1827 1893 Stomach distress Few & bleeding side-effect Analgesic (pain
More informationName 10 Molecular Biology of the Gene Test Date Study Guide You must know: The structure of DNA. The major steps to replication.
Name 10 Molecular Biology of the Gene Test Date Study Guide You must know: The structure of DNA. The major steps to replication. The difference between replication, transcription, and translation. How
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationAntibiotics in the Environment: Natural and Anthropogenic Contributions. Julian Davies UBC,Vancouver
Antibiotics in the Environment: Natural and Anthropogenic Contributions. Julian Davies UBC,Vancouver THE PARVOME (THE UNIVERSE OF BIOACTIVE NATURAL PRODUCTS) uorigins: EVOLUTIONARILY VERY OLD. STRUCTURAL
More informationKey message: How can pharmacological modeling improve research in zebrafish, and how might zebrafish research improve translational pharmacology
Key message: How can pharmacological modeling improve research in zebrafish, and how might zebrafish research improve translational pharmacology 1 Key message: The zebrafish embryo/larva is a relatively
More informationAnswers to Module 1. An obligate aerobe is an organism that has an absolute requirement of oxygen for growth.
Answers to Module 1 Short Answers 1) What is an obligate aerobe? An obligate aerobe is an organism that has an absolute requirement of oxygen for growth. What about facultative anaerobe? 2) Distinguish
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationPIP s Pup s and Problems
PIP s Pup s and Problems Graham Bailey, Senior Scientific Director and Fellow Reproductive and Juvenile Toxicology Drug Safety Sciences Janssen Pharmaceutica N.V Pediatric Medicine Until ~10 years ago,
More informationMerging the Science of Quantitative Pharmacology into Routine Patient Care: Focus on Digital Tools
Merging the Science of Quantitative Pharmacology into Routine Patient Care: Focus on Digital Tools Janel Long-Boyle, PharmD, PhD Associate Professor of Clinical Pharmacy UCSF School of Pharmacy Disclosure(s)
More informationExpectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products
Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products Approved by the IPRP Management Committee on 3 June 2018 12 April 2018 Table of Contents 1. Position Statement... 3 2. Executive
More informationVoriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012
Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0 20 May 2012 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationRegulatory Perspective on Developing Long Acting ARVs for HIV Treatment/Prevention. FDA Division of Antiviral Products
Regulatory Perspective on Developing Long Acting ARVs for HIV Treatment/Prevention FDA Division of Antiviral Products None Financial Disclosures FDA Disclaimer The views in this presentation represent
More informationPHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATIONS Principles, Methods, and Applications in the Pharmaceutical Industry
More informationPHARMACOLOGY - II. Dr Shariq Syed Associate Professor AIKTC, SoP
PHARMACOLOGY - II Dr Shariq Syed Associate Professor AIKTC, SoP PHARMACOLOGY!! EXCITING STUFF WE WILL EXPLORE THIS SEM Chemotherapy 30 hrs Immunomodulators 9 hrs Drugs for Endocrine systems 11 hrs Hematological
More informationLecture Series 10 The Genetics of Viruses and Prokaryotes
Lecture Series 10 The Genetics of Viruses and Prokaryotes The Genetics of Viruses and Prokaryotes A. Using Prokaryotes and Viruses for Genetic Experiments B. Viruses: Reproduction and Recombination C.
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationReflection paper on dose optimisation of established veterinary antibiotics in the context of SPC harmonisation
1 2 3 19 July 2018 EMA/CVMP/849775/2017 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 7 Reflection paper on dose optimisation of established veterinary antibiotics in the context of
More informationOrganic Pharmaceutical Chemistry: Prodrugs
Organic Pharmaceutical Chemistry IV 1st Semester, Year 5 (2016-2017) Lecture 1 Organic Pharmaceutical Chemistry: Prodrugs Dr Asim A. Balakit Pharmaceutical Chemistry Dept., College of Pharmacy, Babylon
More informationPharmacokinetics in clinical oncology
Pharmacokinetics in clinical oncology Carlos Ochoa Biostatistics Journal Club Zurich, 27 March 2013 Pharmacokinetics in clinical oncology Anticancer drug effects: Shrink tumour size Slow tumour growth
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More information